# Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone

> **NCT03707184** · PHASE2 · COMPLETED · sponsor: **University of Utah** · enrollment: 17 (actual)

## Conditions studied

- Metastatic Prostate Carcinoma
- Prostate Carcinoma Metastatic in the Bone
- Stage IV Prostate Cancer

## Interventions

- **PROCEDURE:** Computed Tomography
- **DRUG:** Fluciclovine F18
- **PROCEDURE:** Positron Emission Tomography

## Key facts

- **NCT ID:** NCT03707184
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-02
- **Primary completion:** 2022-02-03
- **Final completion:** 2022-02-03
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2024-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03707184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03707184, "Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03707184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*